Riverside Partners

The three General Partners — David Belluck, Steve Kaplan, and Craig Stern — run investment decisions. Belluck has been with the firm since 1992 and chairs the investment committee. Kaplan joined in 2006 with operating experience at Harris Graphics and The Coleman Company plus a stint as a BCG partner. Stern joined in 2012 after investing in technology and media at Providence Equity Partners and General Atlantic.

Riverside invests directly — the firm does not operate as a fund of funds. It writes equity checks for control buyouts and minority growth investments, and it funds add-on acquisitions through its portfolio companies. The firm does not mention making LP commitments to outside managers.

Riverside targets companies generating $3 million to $15 million in EBITDA. The firm describes itself as focused on small- and medium-sized companies that are leaders in their niche. Add-on acquisitions can fall below that range, and the firm states it will pursue value-accretive add-ons "of any size."

The firm explicitly operates in only two sectors — technology and healthcare — and does not pursue consumer, industrials, financial services, or energy investments. Within healthcare, confirmed subsectors include medical products, provider services, contract manufacturing, pharma services, lab products, and healthcare IT. Technology subsectors include software, telecommunications, information services, tech-enabled business services, and transaction processing.

Riverside Partners is unrelated to The Riverside Company — a global private equity firm also focused on the middle market but headquartered in New York and Cleveland. Riverside Partners has always been Boston-based and exclusively invests in technology and healthcare, while The Riverside Company operates across multiple sectors and geographies.